BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Molecula Research Labs, A CalbaTech, Inc. Company, Receives License To Key RNAi Patent


10/19/2005 5:09:31 PM

IRVINE, Calif., and HERNDON, Va., Dec. 15 /PRNewswire-FirstCall/ -- CalbaTech, Inc. (BULLETIN BOARD: CLBE) , which is focused on acquiring, incubating and developing early stage life science companies and technologies, today announced that Molecula ( http://www.molecula.com/ ), Herndon, Virginia, a subsidiary of CalbaTech, received a non-exclusive license to Patent 6,506,599, "Genetic Inhibition by Double-Stranded RNA," from the Carnegie Institution of Washington.

Matt Maupin, Molecula CEO, stated that "Molecula is one of the leading companies in gene silencing technologies for gene and protein function studies. This is the most important patent in RNAi technology, and this license allows Molecula to aggressively compete in the RNAi market, which is expanding at an enormous rate. This is the most widely licensed patent relating to RNAi technology and allows Molecula to complete important distribution and partnership agreements that have been pending for some time."

Molecula's technology permits delivery of active siRNA or antisense to target genes with a high rate of success. Molecula has particular expertise in design technology and has been in the gene silencing business for ten years with its antisense design technology.

Molecula plans on offering a comprehensive RNAi portfolio, and is in discussions with major international partners to provide its RNAi products worldwide. Molecula also sells transfection reagents, The Inducer(TM) -- a novel IPTG replacement for increased protein expression, neuropeptides and biochemicals.

The Carnegie Institution ( http://www.carnegieinstitution.org/ ), Washington, D.C., has been a pioneering force in basic scientific research since 1902. It is a private, nonprofit organization with six research departments in the U.S.: Embryology, Geophysical Laboratory, Terrestrial Magnetism, The Observatories, Plant Biology, and Global Ecology.

CalbaTech, Inc. (BULLETIN BOARD: CLBE) is an emerging life sciences company that is concentrating on providing products and platforms to the research market, both for biotech and pharmaceutical companies, as well as academic institutions. CalbaTech is focused on acquiring, incubating and developing early stage life science companies and next generation products and technologies, both in the United States and the United Kingdom. In addition to growth through acquisition, CalbaTech is focused on breakthrough innovation in areas of biological discovery. More information is available at http://www.calbatech.com/ .

Note: Certain statements in this news release may contain "forward looking" information within the meaning of rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Act of 1934 and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, may include forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will be accurate and actual results and future events could differ materially from those anticipated in such statements.

CalbaTech, Inc.

CONTACT: E & E Communications, +1-949-707-5365,pknopick@eandecommunications.com , for CalbaTech, Inc.


Read at BioSpace.com

Related News

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->